中国临床药理学杂志2026，Vol.42Issue(4)：552-558,7.DOI:10.13699/j.cnki.1001-6821.2026.04.016
新型非典型抗精神病药布瑞哌唑的研究现状
Research status of new atypical antipsychotic drugs breziprazole
摘要
Abstract
Brexpiprazole,a novel atypical antipsychotic drug,has therapeutic effects in the treatment and prevention of relapse of schizophrenia.It exerts its efficacy through partial agonism of dopamine D2 receptor and 5-hydroxytryptamine receptor 1A(5-HT1A),as well as antagonism of 5-HT2A receptor.In terms of pharmacokinetics,it features high oral bioavailability,a long half-life,and minimal influence of food on its absorption.Multiple clinical trials have confirmed its effectiveness in the acute treatment(2-4 mg every day)and maintenance treatment(1-4mg every day)of schizophrenia.Regarding safety,common adverse reactions include akathisia and weight gain,with a relatively low risk of metabolic abnormalities.No systematic review of brexpiprazole has been published in China.This article conducts a systematic search for the first time and reviews it from aspects such as its mechanism of action,pharmacokinetic characteristics,clinical efficacy,and safety,providing a reference for rational clinical use.关键词
布瑞哌唑/精神分裂症/多巴胺受体/非典型抗精神病药Key words
brexpiprazole/schizophrenia/dopamine receptors/atypical antipsychotics分类
医药卫生引用本文复制引用
张红玉,王楠,沙莎,贾菲..新型非典型抗精神病药布瑞哌唑的研究现状[J].中国临床药理学杂志,2026,42(4):552-558,7.基金项目
北京药学会临床药学研究基金资助项目(LCYX-2024-14) （LCYX-2024-14）
北京市医院管理中心"扬帆3.0"医工结合培育基金资助项目(YGLX202537) （YGLX202537）
